FGFR1 is an inclusion eligibility criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR3 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for infiltrating renal pelvis and ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and infiltrating renal pelvis and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].